Big Patent Expirations of 2010
While the much-talked-about patent cliff won't hit until 2011, 2010 will still see patent expirations of some of the industry's blockbuster drugs. Teva, Apotex, Mylan and a slew of other generic drugmakers will have a chance to put a dent in the sales of a number of brand meds this year--including Flomax and Aricept. Lipitor, whose basic patent expires this year, doesn't face competition until 2011 because of Pfizer's deal with Ranbaxy, the first-filer. It's still included in the following list, which has a number of top-selling drugs.
Our 2010 patent expiration list also includes drugs whose patent actually expires, but managed to get a six-month extension due to pediatric exclusivity. Report
1. Cozaar/Hyzaar - Merck
2. Lipitor - Pfizer
3. Flomax - Boehringer Ingelheim
4. Arimidex - AstraZeneca
5. Climara - Bayer HealthCare
6. Aricept - Aricept
7. Invirase - Roche
8. Hycamtin - GlaxoSmithKline
9. Protonix - Pfizer
10. Levaquin - Levaquin
Comments
Good to have this basic information. Good if someone can analyze the trend of new product launches, patent expiry and suggest if industry is sitting on a low R&D projects/ products and its implication on the overall pharma/ therapeutic market.
Also it is worth to note that out of all the 10 patent expiry, what are the key strategies players have deployed to reduce the impact of generisation (e.g. Lipitor's agreement with Ranbaxy).
Dr. Ambrish Joshi
What's important is to look at the size of each of these products as proprietary drugs and then estimate what could be the fall of prices after patent expiry, and then asess the real potential available for the generic players.....As Teva, Mylan, Apotex will invariably target this market, how will the generic space look like for mid size companies to formulate their startegies????
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities

SHARE
WITH: